Pozen Inc. (POZN)

Pozen Inc. (POZN) is one of our top-picks for small-cap biotech. We see the fundamentals as strong and the valuation as absurdly low.

Treximet trends are improving and sales should start to dramatically improve in the coming months. Plus, with the FDA recently confirming the primary endpoint in the phase III PN clinical trials, Pozen and partner AstraZeneca should be in position to file for approval of PN by the middle of the year.

Phase III plans for PA are also moving forward and should begin by the third quarter. We see both products as $500 million opportunities. By 2013, we think Pozen can deliver revenues close to $200 million, with net income well above $100 million.

Pozen Inc. (POZN) : FULL ANALYST REPORT

Read the full analyst report on POZN